NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported after the close of the market Tuesday that its third quarter revenues grew more than four-fold year over year amid a sharp increase in revenues from its pharmaceutical partners.

For the three-month period ended Sept. 30, HTG's total revenues climbed to $3.7 million from $913,901 in the same period a year earlier. Third quarter service revenues rose to $3.1 million from $407,836, with collaboration agreement revenue from pharma clinical programs accounting for $2.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.